データなし
コード銘柄名
現在値変化額変化率出来高売買代金始値前日終値高値安値時価総額浮動株時価株式総数浮動株5日変化率10日変化率20日変化率60日変化率120日変化率250日変化率年初来配当利回売買回転率直近PER前年PER振幅業種
お気に入り
89bio to Participate in the UBS Global Healthcare Conference
Madrigal, 89Bio Jump After Novo's Semaglutide Shows Promise in MASH
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings
State Street Corp's Strategic Acquisition in 89bio Inc
89bio to Present New Analyses From ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024
89bio Negotiates $50 Million Increase in Borrowing Capacity to $150 Million